Suche
Mein Konto
Breakthrough in cancer research: BioNTech and Bristol Myers with mega deal!
Bristol Myers Squibb is investing $1.5 billion in BioNTech to develop innovative cancer drugs by 2028.
Breakthrough in cancer research: BioNTech and Bristol Myers with mega deal!
In a significant development for cancer therapy, biopharma partner BioNTech has announced a $1.5 billion partnership with US company Bristol Myers Squibb. The aim of this collaboration is to research and develop new, experimental cancer drugs that have the potential to significantly improve patients' lives. vienna.at reports that the deal could even be worth over $11 billion for BioNTech in total.
As part of this partnership, Bristol Myers Squibb will co-develop and commercialize BioNTech's drug BNT327. BNT327 is part of a new class of immunotherapies that aim to harness patients' immune systems to fight cancer. Annual milestone payments of up to $2 billion are planned for BioNTech until 2028.
Development and clinical testing
BNT327 is currently being tested as a first-line therapy for patients with advanced lung cancer. According to information from vienna.at Over 1000 patients have already taken part in the clinical studies. BioNTech is also studying BNT327 for other forms of cancer, including breast cancer and solid tumors. The active ingredient targets the protein PD-L1 and the growth factor VEGF-A, making it a promising candidate in cancer treatment.
The partnership also means that all development and manufacturing costs as well as profits and losses are shared equally between the two partners. Loud Mirror The collaboration is of strategic importance for BioNTech, as it not only expands the company's portfolio but also advances the development of new therapies.
Future outlook
According to the experts at the University of Tübingen, this partnership could significantly advance the research and development of innovative therapies in the fight against cancer. Given the increasing importance of immunotherapies in cancer treatment, BNT327 could play a key role in improving patient survival rates and quality of life. Those interested can find further information on the website University of Tübingen.
Progress in the clinical development of BNT327 will continue to be closely monitored as medicine and treatment options for cancer patients continue to rapidly advance.